A couple weeks ago, I imagined a “dream team“ of people who could break the mold and come up with a more fair, sustainable way for pricing drugs. The goal: Improve access to medicines, improve patient outcomes, and maintain profit incentives for companies to keep developing innovative new ones.
My hope was that VP Joe Biden and the octogenarian pharmaceutical legend Roy Vagelos could chair the committee. The article, first published for subscribers of Timmerman Report on Mar. 7, had 14 other names of people who brought special perspective to the table.
